Associate Director, Oncology Access Marketing at Corcept Therapeutics

Redwood City, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, OncologyIndustries

Requirements

Bachelor’s Degree
8-10 years of pharmaceutical experience
2-5 years in market access marketing (payer, key customer)
Experience with marketing patient support programs
Experience with pull-through platforms and resources
Experience with oral and infused oncology therapies
Strategic mindset and patient centric approach to the business
Ability to thrive in a fast-paced, dynamic environment
Demonstrated collaborative and results oriented work style
Effective oral and written communication skills and ability to engage all levels of the organization
Working knowledge of US health care policies and relevant legal, compliance, and regulatory requirements for pharmaceutical promotions in line with pharma industry guidelines
Uphold Corcept's Key Principles by driving collaboration, embracing possibilities, following the data, and leading by doing, ensuring all initiatives align with the Company's ethics and patient first principles
Some travel required, including trips to Corcept headquarters and travel to meeting locations (25%)

Responsibilities

Patient Support Marketing – Leads the development and execution of tactical marketing plans to deliver patient support materials that promote Corcept’s program to HCPs, patients, and care providers. Collaborate with cross functional teams, especially patient support team and brand marketing team, to support a positive patient and provider access experience. Manage external agency partners, ensuring a timely and financially responsible execution of key marketing initiatives
Pull Through Resources – Oversees the development of the pull-through platform (Example: MMIT FormTrak) and associated resources to communicate payer coverage and access to HCPs and patients
Payer Marketing – Assists in development and execution of payer marketing strategy and materials such pre-approval information exchange (PIE) materials and post-approval payer value resources to support rapid coverage
Key Customer Marketing – Assists in the development of key community oncology customer marketing strategy and materials to remove barriers to adoption. Also, develops materials to communicate product information to key customer segments such as specialty distributors and specialty pharmacies
Uphold Corcept’s Key Principles by driving collaboration, embracing possibilities, following the data, and leading by doing, ensuring all initiatives align with the Company’s ethics and patient-first principles

Skills

Access Marketing

Patient Support Marketing

Payer Strategies

Oncology Marketing

Marketing Plans

Cross-Functional Collaboration

Agency Management

HCP Communications

Pull-Through Resources

MMIT FormTrak

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free